Alembic Straddles Oversupply And Shortages In US
Executive Summary
One-off opportunities lift Alembic’s US generics business in the fiscal second quarter but the market continues to pose challenges amid surging oversupply and price erosion. On the other hand, a string of injectable approvals, including for ketorolac tromethamine, could open up opportunities for the company given the 'on and off' shortages.
You may also be interested in...
Cipla Stays Upbeat On Advair Generic With ‘Superior’ Cost Position, Derisks Abraxane
Generic Revlimid, lanreotide propel Cipla’s US business to a high in the fiscal second quarter, with products like leuprolide depot set for debut ‘any time now’. Management signals cost edge for generic Advair as it awaits further word following a FDA establishment inspection report at its Indian site, while a Plan B is being initiated for generic Abraxane.
Lupin Expands US Inhalation Business With Two Sunovion Brands
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.